Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2011.0191
NEWS & VIEWS
|
Peritoneal recurrence: The challenge in gastric cancer treatment and efforts to prevent.
|
|
Affiliation: Dr. John Spiliotis, Head of Department of Surgery, "METAXA" Cancer Memorial Hospital, Botosi 51, TK 18535, Piraeus, Greece.
E-mail: jspil@in.gr |
Since there is no abstract available we provide the first paragraph.
Standardization of surgery with extended (D2) lymph node dissection and adjuvant systemic treatment with chemotherapy and trastuzumab (Herceptin) for HER2-positive disease in patients with resectable stage II or III gastric cancer, loco-regional and distant recurrence rates and death rates have been reduced. However, peritoneal carcinomatosis still remains the most common cause of treatment failure and death. Peritoneal dissemination is an incurable disease with a median survival of less than 10 months. Can peritoneal recurrence be prevented and how particularly at high-risk patients with advanced serosa invasion (T3,T4) tumor?
(Citation: Gastric & Breast Cancer 2011; 10(4) 232-234)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €33 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
Online
ISSN : 1109 - 7647
Print ISSN : 1109 - 7655
 We
subscribe to the HONcode principles. Verify
here.
please, read our policy about privacy
and confidentiality of information and transparency
of sponsorship
last
update: 9 September 2011 |
|
